Olga Nesterova, Dmitrii Babaskin, Yuliya Tikhonova, Natalia Molodozhnikova, Sergey Kondrashev
Olga Nesterova, Dmitrii Babaskin*, Yuliya Tikhonova, Natalia Molodozhnikova, Sergey Kondrashev
I. M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Volume - 14,
Issue - 5,
Year - 2021
The aim of the research is to study the effect of the synthesis of uracil derivatives on the HIV-1 activity. To achieve the goal, the following tasks were determined: to study the specificity of possible compounds for HIV-1 treatment; to synthesize uracil derivatives; to study the effect of the compounds on HIV-1 replication in vitro and select the most optimal concentrations, considering the cytotoxic effect; to determine the most effective anti-HIV-1 compounds for further research. Thus, nine new uracil analogues have been synthesized and proved to be inhibitors of HIV-1. Key structural modifications included replacement of the 6-chloro group of 1-benzyl-6-chloro-3-(3,5-dimethylbenzyl) uracil by other functional groups or N (1)-alkylation of 3-(3,5-dimethylbenzyl)-5-fluorouracil. These compounds showed only micromolar potency against HIV-1 in MT-4, though two of them; 6-azido-1-benzyl-3-(3,5-dimethylbenzyl) uracil and 6-amino-1-benzyl-3-(3,5-dimethylbenzyl) uracil were highly potent (half maximal effective concentration =0.081 and 0.069µM) and selective (selectivity index =679 and 658), respectively. Structure-activity relationships among the newly synthesized uracil analogues suggest the importance of the H-bond formed between 6-amino group of 6-amino-1-benzyl-3-(3,5-dimethylbenzyl) uracil and amide group of HIV-1 reverse transcriptase. Two 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl) uracils, (6-azido-1-benzyl-3-(3,5-dimethylbenzyl) uracil and 6-amino-1-benzyl-3-(3,5-dimethylbenzyl) uracil) were discovered as novel anti-HIV agents. Compound’s activity against HIV-1 was determined based on inhibition of virus-induced cytopathogenicity in MT-4 cells. The compounds were tested for efficacy in infected cells and cytotoxicity. These compounds should be further pursued for their toxicity and pharmacokinetics in vivo as well as antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant strains. Thus, it will contribute to the development of a new generation of compounds effective against different viruses, considering their quickly mutation and increased resistance.
Cite this article:
Olga Nesterova, Dmitrii Babaskin, Yuliya Tikhonova, Natalia Molodozhnikova, Sergey Kondrashev. Effect of N'-Benzyl Substituted Uracil and the Analogues on HIV-1 Inhibition.Research Journal of Pharmacy and Technology. 2021; 14(5):2723-8. doi: 10.52711/0974-360X.2021.00480
Olga Nesterova, Dmitrii Babaskin, Yuliya Tikhonova, Natalia Molodozhnikova, Sergey Kondrashev. Effect of N'-Benzyl Substituted Uracil and the Analogues on HIV-1 Inhibition.Research Journal of Pharmacy and Technology. 2021; 14(5):2723-8. doi: 10.52711/0974-360X.2021.00480 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-64
1. Nguyen P, Zheng J, Gremminger TJ, Qiu L, Zhang D, Tuske S, Lange MJ, Griffin PR, Arnold E, Chen SJ, Zou X, Heng X and Burke DH. Binding interface and impact on protease cleavage for an RNA aptamer to HIV-1 reverse transcriptase. Nucleic acids research. 2020; 48(5): 2709-2722.
2. Tian L, Kim MS, Li H, Wang J and Yang W. Structure of HIV-1 reverse transcriptase cleaving RNA in an RNA/DNA hybrid. Proceedings of the National Academy of Sciences. 2018; 115(3): 507-512.
3. Yeo JY, Goh GR, Su CT and Gan SK. The determination of HIV-1 RT mutation rate, its possible allosteric effects, and its implications on drug resistance. Viruses. 2020; 12(3): 297.
4. Bivigou-Mboumba B. Human Immunodeficiency Virus-Hepatitis B Virus (HIV-HBV) coinfection. Advances in HIV and AIDS Control. 2018.
5. Vourvahis M, Langdon G, Layton G, Labadie RR, Choo HW, Ndongo MN and Davis J. The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects. Journal of acquired immune deficiency syndromes. 2012; 60(1): 24–32.
6. Wright DW, Deuzing IP, Flandre P, van den Eede P, Govaert M and Setiawan L. A Polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity. PLoS ONE. 2013; 8(10): e74078.
7. Paneth A, Płonka W and Paneth P. (2019). Assessment of nonnucleoside inhibitors binding to HIV-1 reverse transcriptase using HYDE scoring. Pharmaceuticals. 2019; 12(2): 64.
8. Zhuang C, Pannecouque C, De Clercq E and Chen F. Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Acta Pharmaceutica Sinica B. 2019; 10(6): 961-978.
9. Isono Y, Sakakibara N, Ordonez P, Hamasaki T, Baba M, Ikejiri M and Maruyama T. Synthesis of 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives with potential anti-HIV activity. Antiviral Chemistry and Chemotherapy. 2011; 22(2): 57-65.
10. Novikov MS and Geisman AN. Methods for the synthesis of 6-substituted uracil derivatives - the structural basis of antiviral agents. Chemistry of Heterocyclic Compounds. 2013; 10: 1537-1564.
11. Paramonova MP, Babkov DA, Valuev-Elliston VT, Ivanov AV, Kochetkov SN, Pannecouque C, Ozerov AA, Balzarini J. and Novikov MS. Synthesis and Anti-HIV-1 Activity of 1-[ω-(Phenoxy)Alkyl and -Alkenyl]Uracil Derivatives. Pharmaceutical Chemistry Journal. 2013; 47(9): 459-463.
12. Liu Q, Gupta A, Okesli-Armlovich A, Qiao W, Fischer CR, Smith M, Carette JE, Bassik MC and Khosla C. Enhancing the antiviral efficacy of RNA-dependent RNA polymerase inhibition by combination with modulators of pyrimidine metabolism. Cell Chemical Biology. 2020; 27(6): 668-677.
13. Hoffmann HH, Kunz A, Simon VA, Palese P and Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proceedings of the National Academy of Sciences. 2011; 108(14): 5777-5782.
14. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP and Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry. 2020; 295(15): 4773-4779.
15. Novakova L, Pavlík J, Chrenkova L, Martinec O and Cerveny L. Current antiviral drugs and their analysis in biological materials – Part II: Antivirals against hepatitis and HIV viruses. Journal of Pharmaceutical and Biomedical Analysis. 2018: 147: 378-399.
16. Qing M, Zou G, Wang QY, Xu HY, Dong H, Yuan Z and Shi PY. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrobial Agents and Chemotherapy. 2010; 54(9): 3686-3695.
17. Krol E, Wandzik I, Krejmer-Rabalska M and Szewczyk B. Biological evaluation of uridine derivatives of 2-deoxy sugars as potential antiviral compounds against influenza A virus. International journal of molecular sciences. 2017; 18(8): 1700.
18. Geisman AN, Valuev-Elliston VT, Ozerov AA, Khandazhinskaya AL, Chizhov AO, Kochetkov SN. and Novikov M.S. 1,6-Bis[(benzyloxy)methyl]uracil derivatives—Novel antivirals with activity against HIV-1 and influenza H1N1 virus. Bioorganic and Medicinal Chemistry. 2016; 24(11): 2476-2485.
19. Ozerov AA, Novikov MS, Timofeeva YuA, Lobachev AA, Luganchenko AI and Geisman AN. HIV-1 pyrimidine non-nucleoside reverse transcriptase inhibitors - development history and prospects. Bulletin of the Volgograd State Medical University. 2012; 3(43): 10-17.
20. Lobachev AA, Ozerov AA, Novikov MS, Luganchenko AI, Hartman T and Bukheit RU. Optimization of the structure of methylated 1-(benzyloxymethyl)-5-(arylamino) uracil derivatives with anti-hiv-1 activity. Bulletin of the Volgograd State Medical University. 2012; 1(41): 91-93.
21. D'Andrea LD and Romanelli A. Chemical Ligation: Tools for Biomolecule Synthesis and Modification. Wiley, New Jersey, USA. 2017.
22. Naumenko K, Golovan A, Zelena L, Shermolovich Yu, Gudz G and Zagorodnya S. Antiviral and apoptosis modulating potential of fluorinated derivatives of uracil. ScienceRise: Biological Science. 23; 1(10): 31-38.
23. Matyugina ES, Kochetkov SN and Khandazhinskaya AL. 5’-norcarbocyclic analogues of nucleosides as potential chemotherapeutic agents. 2016; 8(3): 74-79.
24. Sakakibara N, Baba M, Okamoto M, Toyama M, Demizu Y, Misawa T and Maruyama T. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives. Antiviral Chemistry and Chemotherapy. 2015; 24(1): 3-18.
25. Yumashev AV, Utyuzh AS, Volchkova IR, Mikhailova MV and Kristal EA. The influence of mesodiencephalic modulation on the course of postoperative period and osseointegration quality in case of intraosseus dental implantation. Indian Journal of Science and Technology. 2016; 9(42): 104307.